Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Employees - 12,
CEO - Mr. Yat-Gai Au,
Sector - Healthcare,
Country - HK,
Market Cap - 316.21M
Altman ZScore(max is 10): 832.24, Piotroski Score(max is 10): 2, Working Capital: $7920435, Total Assets: $8438211, Retained Earnings: $-21616903, EBIT: -5694769, Total Liabilities: $219512, Revenue: $0
AryaFin Target Price - $0.22 - Current Price $24.30 - Analyst Target Price $-
| Ticker | RGC |
| Index | - |
| Curent Price | 24.30 |
| Change | 3.27% |
| Market Cap | 316.21M |
| Average Volume | 672.03K |
| Income | -4.30M |
| Sales | 0.00M |
| Book Value/Share | 0.63 |
| Cash/Share | 0.61 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | Feb 15, 2018 |
| Employees | 12 |
| Moving Avg 20days | -6.39% |
| Moving Avg 50days | 89.01% |
| Moving Avg 200days | 211.27% |
| Shares Outstanding | 13.01M |
| Earnings Date | - |
| Inst. Ownership | 0.24% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | - |
| Price/Book | 38.47 |
| Price/Cash | 39.72 |
| Price/FCF | - |
| Quick Ratio | 41.92 |
| Current Ratio | 41.92 |
| Debt/Equity | 0.01 |
| Return on Assets | -40.85% |
| Return on Equity | -42.49% |
| Return on Investment | -52.18% |
| Gross Margin | - |
| Ops Margin | - |
| Profit Margin | - |
| RSI | 50.93 |
| BETA(β) | -4.32 |
| From 52week Low | 701.98% |
| From 52week High | -64.78% |
| EPS | -0.33 |
| EPS next Year | - |
| EPS next Qtr | - |
| EPS this Year | - |
| EPS next 5 Year | - |
| EPS past 5 Year | -60.65% |
| Sales past 5 Year | 0.00% |
| EPS Y/Y | 26.73% |
| Sales Y/Y | - |
| EPS Q/Q | 15.45% |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | - |
| ATR(14) | 8.30 |
| Perf Week | -30.31% |
| Perf Month | 475.83% |
| Perf Quarter | 391.90% |
| Perf Year | 244.19% |
| Perf YTD | 391.90% |
| Target Price | - |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer